Log in

NASDAQ:CGIX - Cancer Genetics Stock Price, Forecast & News

-0.24 (-5.30 %)
(As of 02/19/2020 02:22 AM ET)
Today's Range
Now: $4.29
50-Day Range
MA: $4.74
52-Week Range
Now: $4.29
Volume24,644 shs
Average Volume73,986 shs
Market Capitalization$9.01 million
P/E RatioN/A
Dividend YieldN/A
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:CGIX



Sales & Book Value

Annual Sales$27.47 million
Book Value$7.37 per share


Net Income$-20,370,000.00


Market Cap$9.01 million
Next Earnings Date4/21/2020 (Estimated)

Receive CGIX News and Ratings via Email

Sign-up to receive the latest news and ratings for CGIX and its competitors with MarketBeat's FREE daily newsletter.

Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How were Cancer Genetics' earnings last quarter?

Cancer Genetics Inc (NASDAQ:CGIX) announced its earnings results on Tuesday, April, 16th. The medical research company reported ($0.14) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.02. The medical research company earned $6.80 million during the quarter. Cancer Genetics had a negative net margin of 59.28% and a negative return on equity of 139.59%. View Cancer Genetics' Earnings History.

When is Cancer Genetics' next earnings date?

Cancer Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, April 21st 2020. View Earnings Estimates for Cancer Genetics.

Has Cancer Genetics been receiving favorable news coverage?

Headlines about CGIX stock have been trending positive on Wednesday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cancer Genetics earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View News Stories for Cancer Genetics.

Are investors shorting Cancer Genetics?

Cancer Genetics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 28,500 shares, a decrease of 65.0% from the January 15th total of 81,400 shares. Based on an average trading volume of 664,200 shares, the short-interest ratio is currently 0.0 days. Currently, 1.5% of the shares of the company are short sold. View Cancer Genetics' Current Options Chain.

Who are some of Cancer Genetics' key competitors?

What other stocks do shareholders of Cancer Genetics own?

Who are Cancer Genetics' key executives?

Cancer Genetics' management team includes the folowing people:
  • Mr. John A. Roberts MBA, Pres, CEO, COO & Director (Age 60)
  • Mr. Michael Glenn Miles, Chief Financial Officer
  • Mr. Michael Brian McCartney, Chief Commercial Officer
  • Mr. William Lansing Finger, Exec. VP of Precision Medicine & Biopharma Solutions
  • Dr. Ralf Brandt, Pres of Discovery & Early Devel. Services (Age 56)

Who are Cancer Genetics' major shareholders?

Cancer Genetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (8.00%), Oxford Asset Management LLP (1.12%) and Bank of Montreal Can (0.48%). Company insiders that own Cancer Genetics stock include John A Roberts, John Pappajohn and Michael Glenn Miles. View Institutional Ownership Trends for Cancer Genetics.

Which major investors are selling Cancer Genetics stock?

CGIX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Cancer Genetics.

Which major investors are buying Cancer Genetics stock?

CGIX stock was acquired by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP and Bank of Montreal Can. Company insiders that have bought Cancer Genetics stock in the last two years include John A Roberts, John Pappajohn and Michael Glenn Miles. View Insider Buying and Selling for Cancer Genetics.

How do I buy shares of Cancer Genetics?

Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $4.29.

How big of a company is Cancer Genetics?

Cancer Genetics has a market capitalization of $9.01 million and generates $27.47 million in revenue each year. Cancer Genetics employs 150 workers across the globe.View Additional Information About Cancer Genetics.

What is Cancer Genetics' official website?

The official website for Cancer Genetics is http://www.cancergenetics.com/.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]

MarketBeat Community Rating for Cancer Genetics (NASDAQ CGIX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  388 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  603
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe CGIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel